Interstitial lung diseases (ILDs) represent an extensive group of pulmonary disorders, characterized by inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILDs, their etiology, clinical manifestations, diagnostic tools, and treatment options.
ILDs can be idiopathic or associated with various conditions such as connective tissue diseases, environmental exposures, and certain medications. Idiopathic pulmonary fibrosis (IPF) is the most common form of ILDs. Other types include nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, and hypersensitivity pneumonitis.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles and finger clubbing. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity for carbon monoxide.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs. It can identify characteristic patterns such as honeycombing, ground-glass opacities, and traction bronchiectasis. In certain cases, a lung biopsy may be necessary for definitive diagnosis.
Treatment of ILDs is primarily aimed at reducing inflammation and fibrosis, and managing symptoms. Corticosteroids and immunosuppressive agents are commonly used. For IPF, specific antifibrotic agents such as pirfenidone and nintedanib have shown efficacy. Lung transplantation may be considered for suitable candidates.
ILDs are complex disorders requiring a comprehensive diagnostic approach and individualized treatment strategies. Early recognition and appropriate management can significantly improve patient outcomes. Continued research is necessary to further our understanding of these diseases and develop more effective therapeutic options.
1.
Pickleball program boosts health and wellness for cancer survivors, study finds
2.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
3.
Study recommends new grading system for invasive squamous cell carcinoma of the lung
4.
Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?
5.
In inflammatory breast cancer, ER beta regulates estrogen signaling.
1.
Hematopoietic Aging and Long-Term Disease Risk: Mechanisms, Clinical Impact, and Emerging Therapeutic Strategies
2.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
3.
Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals
4.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
5.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation